lundi 9 décembre 2019

Onco Actu du 9 décembre 2019


2.13 ETIOLOGIE - NDMA



EMA update on metformin diabetes medicines [EMA]











3.1.1 PRÉVENTION - TABAC - E-CIGS



Update: Demographic, Product, and Substance-Use Characteristics of Hospitalized Patients in a Nationwide Outbreak of E-cigarette, or Vaping, Product Use–Associated Lung Injuries — United States, December 2019 [CDC]











5.10 TRAITEMENTS - ESSAIS



BRAF Inhibitor Shows Promising Results in Pediatric Patients with Low-Grade Glioma [AACR]











5.12.2 IMMUNOTHÉRAPIES - CAR-T, THÉRAPIES CELLULAIRES



Novartis downsizing internal efforts on CAR T in solid tumors [BioCentury]










5.12.5 IMMUNOTHÉRAPIES - PHARMA



Watch out, Keytruda. Ferring's bladder cancer gene therapy rival has new data—and they look competitive [Fierce Pharma]











Janssen Announces BCMA CAR-T Therapy JNJ-4528 Granted U.S. FDA Breakthrough Therapy Designation for the Treatment of Relapsed or Refractory Multiple Myeloma [Janssen]











5.12.8 IMMUNOTHÉRAPIES - ECONOMIE



Swiss approve insurance cover for Novartis, Gilead cell therapies [Reuters]











5.2.6 PHARMA - BIOTECH



On the heels of a PhIII implosion, cancer biotech Mologen is turned over to the liquidator [EndPoints]











Black Diamond raises another $85M to bring new oncogene approach into clinic [EndPoints]











5.3 TRAITEMENTS - FDA, EMA, NICE...



FDA Approving Drugs at Breakneck Speed, Raising Alarm [Bloomberg]










5.7 SABCS



SABCS to Showcase Advances in Breast Cancer Treatments [Cancer Research Catalyst]











5.8.1 ASH - COMMUNIQUÉS



The Leukemia & Lymphoma Society (LLS) and The American Society of Hematology (ASH) Team Up to Connect Blood Cancer Patients to Clinical Trials that Can Lead to New and Better Treatments [ASH]











5.8.2 ASH - PHARMA



Findings Released from Real-World Data Analysis of Eliquis (apixaban) for the Treatment of Venous Thromboembolism in Patients with Active Cancer [Pfizer]











5.8.4 ASH - CAR-T



Bristol-Myers Squibb Announces Studies Evaluating liso-cel in Multiple Additional Patient Populations, Site of Care and Disease Areas Presented at American Society of Hematology (ASH) Annual Meeting [BMS]











New Approaches Aim to Enhance CAR T-Cell Therapy [ASH]











5.8.5 ASH - MYÉLOME MULTIPLE



Myeloma cell therapies, now in pharma hands, move into spotlight [Biopharma Dive]










ASH: Gilead Sciences touts 'astounding' Yescarta survival results at 3 years [Fierce Pharma]











Next Wave for CAR T-Cell Therapy Brings Off-the-Shelf, Multiple Myeloma Therapies [AJMC]











Janssen Presents Initial Results for BCMA CAR-T Therapy JNJ-4528 Showing Early, Deep and High Responses in the Treatment of Relapsed or Refractory Multiple Myeloma [Janssen]











J&J team shows off 'breakthrough' BCMA CAR-T data, and that could cause a big headache at bluebird and Bristol-Myers [EndPoints]











Bristol-Myers Squibb and bluebird bio Announce Positive Top-line Results from the Pivotal Phase 2 KarMMa Study of Ide-cel in Relapsed and Refractory Multiple Myeloma [BMS]











5.8.6 ASH - LEUCÉMIES



IMBRUVICA® (ibrutinib) Plus VENCLEXTA®/VENCLYXTO® (venetoclax) Combination Data Show High Rates of Disease Clearance in Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL) [AbbVie]











5.8.6.1 ASH - LEUCÉMIES - ACALABRUTINIB



ASH: AstraZeneca's Calquence posts sky-high survival numbers in previously untreated CLL [FiercePharma]











Calquence significantly prolonged the time patients lived without disease progression or death in previously untreated chronic lymphocytic leukaemia [AstraZeneca]











5.8.6.2 ASH - LEUCÉMIES - IBRUTINIB



Extended Follow-up Phase 3 Data Underscore Sustained Efficacy and Safety of IMBRUVICA® (ibrutinib) in the Treatment of Chronic Lymphocytic Leukemia (CLL) [AbbVie]











IMBRUVICA® (ibrutinib) Combination Therapy Data From Two Studies and Long-Term Integrated Analysis Presented at ASH 2019 Show Efficacy and Safety in First-Line Treatment of Chronic Lymphocytic Leukemia [Janssen]











E1912 follow-up shows ibrutinib effective, well tolerated by majority of CLL patients [ECOG-ACRIN]











5.8.6.3 ASH - LEUCÉMIES - VENETOCLAX



ASH: AbbVie, Roche pad their case for fixed-duration Venclexta use in CLL [FiercePharma]











New Long-Term Data Continues to Demonstrate Progression-Free Survival and Overall Survival Benefits with VENCLEXTA®/ VENCLYXTO® (venetoclax) Combination in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) [AbbVie]











New data demonstrate the continued clinical benefit of fixed-duration, chemotherapy-free Venclexta/Venclyxto-based treatments in chronic lymphocytic leukaemia [Roche]











5.8.7 ASH - LYMPHOMES



More than Seven-Year Analysis of Early Treatment with IMBRUVICA® (ibrutinib) Monotherapy Showed Improved Progression-Free Survival in Patients with Mantle Cell Lymphoma (MCL) that Relapsed or Were Unresponsive to Prior Regimen [AbbVie]











MSK Experts Report Advances in Lymphoma Treatment at the 2019 ASH Meeting [Memorial Sloan Kettering Cancer Center]











Lymphoma Patients May Have New Path to Remission, Even When CAR T Therapy Fails [Penn Medicine]











Bristol-Myers Squibb Announces Liso-Cel Met Primary and Secondary Endpoints in TRANSCEND NHL 001 Study [BMS]











Kite Announces Long-term Data From ZUMA-1 Showing Approximately Half of Refractory Large B-cell Lymphoma Patients Were Alive Three Years After Yescarta Treatment [Gilead]











Bristol-Myers reports positive data on cancer treatment acquired in Celgene deal [Reuters]











Half of lymphoma patients alive three years after Gilead cell therapy treatment: study [Reuters]











6. LUTTE CONTRE LES CANCERS



'Holy grail' of cancer cure hides progress made, says charity [The Guardian]











Cancer research offers more hope than people think [Institute of Cancer Research]










6.10.1 POLITIQUES (USA)



Labor Unions Team Up With Drug Makers to Defeat Drug-Price Proposals [NY Times]











6.11 PATIENTS



‘I’m more stressed about my money than my cancer’: the hidden cost of living with a serious illness [The Telegraph]